Abstract
Previous studies suggested that the SH2-containing inositol- 5- xjiang@bacancer.bc.ca
Introduction
CML is a clonal myeloproliferative disorder characterized in the initial chronic phase of the disease by an excessive production of granulocytes and the presence of a unique rearrangement of the BCR gene on chromosome 22 and the ABL gene on chromosome 9. 1 The 210 kD product of the BCR-ABL fusion gene has increased tyrosine kinase activity 2 that is important to its leukemogenic activity. 3 Cells expressing the BCR-ABL gene, including primary CML cells,
show alterations in many intracellular signaling pathways including the Ras, PI3 kinase, and JAK/STAT pathways. 4, 5 Some of these perturbations may be direct through interactions with the multiple protein-binding domains of p210 BCR-ABL. However, others are likely to represent the downstream consequences of these events, that include the activation of an unusual autocrine mechanism involving interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF). 6, 7 This complexity of intracellular effects caused directly or indirectly by the BCR-ABL oncoprotein, coupled with the relatively small numbers of CML stem cells present in patients with chronic phase disease has made it very difficult to identify the molecular basis of the perturbed biology of these particular cells. 1, 8 SHIP is a 145-kD protein first identified by its ability to interact with SHC following its transient tyrosine phosphorylation in growth factor-activated hematopoietic cells. 9, 10 Subsequent studies revealed SHIP to be a SH2-containing inositol phosphatase that hydrolyzes the 5'-phosphate from inositol-1,3,4,5-tetraphosphate and phosphatidylinositol(PI)-3,4,5-triphosphate.
The latter appears to play a key role in modulating the ability of certain proteins containing pleckstrin homology domains (e.g., Btk, PKB/Akt, PDK1, GRP1, Vav and PLC 1) or SH2
domains (e.g., PI3 kinase and PLC 1) to be translocated to the plasma membrane. 10 SHIP expression is confined to hematopoietic cells (reviewed in 11 ) and targeted disruption of the SHIP For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From gene confers on hematopoietic progenitor cells a hypersensitivity to many growth factors, in vivo expansion of granulocyte-macrophage progenitor numbers and the development of a myeloproliferative syndrome. 12 In cells expressing BCR-ABL, SHIP is constitutively phosphorylated and co-precipitates with p210 BCR-ABL 13-15 although the level of SHIP expression is markedly reduced in some of these cells. 16 A related protein, SHIP2 was also found to be constitutively tyrosine phosphorylated and bound to BCR-ABL in CML cells. 17 These findings suggested that SHIP might play a tumor suppressor-like role in BCR-ABL-mediated leukemia.
To investigate this possibility, we initially compared the frequency and biological 
Materials and methods

Virus
The MSCV-BCR-ABL-IRES-GFP (BCR-ABL) and control MSCV-IRES-GFP (MIG) vectors have been described previously. 7 Ecotropic Phoenix packaging cells 18 Louis, MO), to which 100 ng/mL murine Steel Factor (SF, purified from cDNA-transfected COS cell supernatants), 10 ng/mL murine IL-3 (StemCell) and 10 ng/mL human IL-6 (Cangene, Mississauga, ON) were also added. The cells were then collected and resuspended at 5 x 10 5 cells/mL in VCS diluted 1:3 in Dulbecco's modified Eagle's medium (DMEM) containing 15%
FCS, protamine sulfate (5 µg/mL) and SF IL-3, and IL-6 at the same concentrations as previously. The cells were then transferred to petri dishes that had been pre-coated with 3 µg/cm 2 fibronectin (Sigma) and pre-loaded with virus for 30 minutes at room temperature. 21 This transduction was repeated once 4 hours later. The cells were then incubated at 37 C° for a further 24-48 hours before additional studies as indicated. 
Human Cells
Progenitor assays
Murine colony-forming cell (CFC) and longterm culture-initiating cell (LTC-IC) assays were performed using culture media from StemCell Technologies. CFC assays were performed in FCS-containing methylcellulose cultures with 10 ng/mL human IL-6, 10 ng/mL murine IL-3, 50 ng/mL murine SF and 3 units/mL human erythropoietin [EPO, StemCell]). Colony counts were performed after 12 to 14 days of incubation at 37°C using standard scoring criteria. 23 LTCs were set up on pre-established irradiated mouse marrow LTC feeder layers and maintained at 33°C
with weekly half medium changes and addition of fresh hydrocortisone (10 -6 mMol) prior to performing CFC assays on the cells harvested after 4 weeks as previously described. clones were then expanded in DMEM containing 10% FCS, 100 ng/mL SF, 10 ng/mL IL-3 and 10 ng/mL IL-6, or 5% pokeweed mitogen (PWM)-stimulated murine spleen cell conditioned medium (StemCell). In some experiments, 0.1 to 10 µmol STI571 (Novartis, Basel, Switzerland)
was added to some of the cultures.
Quantitative real-time reverse transcriptase (RT)-PCR analyses
Total RNA was extracted from aliquots of cells using the Absolutely RNA Microprep kit 
Southern analyses
High molecular weight DNA was isolated using DNAZol (GIBCO/BRL). Fifteen µg of DNA was digested with EcoR1, electrophoresed and transferred to a nylon membrane. 6 The blot was then hybridized with a GFP probe derived from the retroviral vector, and a BCR-ABL cDNA was used to confirm the presence of an intact BCR-ABL gene.
Western analyses
10 5 cells were lysed in phosphorylation solubilization buffer (PSB; 50 mMol Hepes buffer, 100 mMol NaF, 10 nMol sodium pyrophosphate, 2mMol Na3VO4, 4 mMol EDTA) containing 0.5% Nonidet P-40 15 and Western analyses performed using a monoclonal anti-ABL antibody (8E9, Pharmingen, Mississauga, ON), an anti-phosphotyrosine antibody (4G10, Upstate Biotechnology, Lake Placid, NY), anti-STAT5A antibodies (Upstate Biotechnology), a monoclonal anti-SHIP antibody (P1C1, Santa Cruz Biotechnology, Santa Cruz, Ca), 2 polyclonal anti-SHIP antibodies against the SH2 domain and c-terminal region of SHIP ( -SHIP166), an anti-SHIP2 antibody 17 and a monoclonal human anti-actin antibody (Sigma, Saint Louis, Missouri).
Transplantation experiments
Hematopoietic stem cells (HSCs) were enumerated using a limiting dilution transplantation assay for cells with competitive, long-term, lympho-myeloid repopulating activity as described previously. 23, 28 Briefly Table 2 , it can be seen that significant effects on survival were restricted to mice transplanted with very small shown) were also consistently detected in these BM cell suspensions including harvests from clonally repopulated mice, indicating the reproducible multi-lineage character of the clones generated. Splenomegaly and hepatomegaly was also frequently seen in these mice.
Transplantation of BM or spleen cells from primary diseased mice produced a similar multilineage lethal disease when transplanted into secondary recipients (n=6, data not shown).
For For For Table 1 ). The leukemogenic properties of the BCR-ABL-transduced Sca-1 + lin -SHIP -/-BM cells were then analyzed. As can be seen in Table 2 and Figures 2-4 , the frequency of these SHIP -/-L-ICs and the clonal, multi-lineage disease they produced with a prolonged latency when injected at limiting dilution were indistinguishable from the results obtained with BCR-ABL-transduced +/+ cells. SHIP -/-leukemias were also similarly transplantable into secondary mice (n = 6, data not shown).
To determine whether differences in p210 BCR-ABL expression or general protein tyrosine phosphorylation might, nevertheless, be discerned in the leukemic cells generated in vivo from +/+ and SHIP -/-cells, Western blot analysis was performed on extracts of cells harvested from mice with splenomegaly or hepatomegaly. As illustrated in Figure 5 , no significant difference could be seen in any of these parameters between leukemias of either genotype. Interestingly, however, for both genotypes, there was evidence of a higher tyrosine phosphorylation of Also as expected, 7 these values were increased in the assays of BCR-ABL-transduced +/+ cells (~6-fold, Table 4 for 16-24 hours (n = 5, Figure 8A ) and Western analysis of SHIP protein levels showed these
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From were also not changed, even though this treatment was sufficient to reduce the extent of tyrosine phosphorylation of the p210 BCR-ABL being expressed ( Figure 8B ). Figure 9B ). Thus, in these leukemic cells, transcript levels were not predictive of protein expression. Reprobing of the Western blots with an antibody to SHIP2, 17 showed that expression of SHIP2 protein was also down-regulated in these cells (data not shown).
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Discussion
Mouse models of human leukemogenesis offer powerful systems to investigate the mechanisms involved in disease latency and the role of specific gene products in disease progression. Transplantation of HSC-enriched fractions of mouse BM cells transduced with the BCR-ABL oncogene encoded in a retroviral vector is now widely used for this purpose. 37 However, when large numbers of transduced cells are transplanted, the recipients develop rapidly lethal polyclonal leukemias which precludes investigation of factors that affect the relatively slow amplification in vivo of isolated leukemic clones characteristic of the early stages of development of human CML. Recently we 7 and others 38 have shown that prior culture of the BCR-ABL-transduced mouse BM cells offers one approach to increasing by several weeks the latency of disease obtained. However, it is difficult to control the composition of the population ultimately transplanted using this type of strategy and the culture conditions used can also variable alter mechanisms initially operative in the transduced cells.
In the present study, we have used an alternative approach. This involved isolating highly . It has reported that a dominant-negative mutant of PKB/AKT inhibits BCR-ABLmediated transformation 40 and AKT is highly phosphorylated in BCR-ABL-transduced BM cells but not in cells transduced with a SH3 deletion mutant of c-abl. 41 BAD has been reported to be a key substrate of AKT. 42 Interestingly, SHIP has also been found to be involved in the regulation of AKT in normal hematopoietic cells 43 . Future investigations will be required to elucidate how altered levels of SHIP contribute to perturbed PI3 kinase signaling in BCR-ABL-expressing cells.
The regulation of expression of the SHIP gene in normal hematopoietic cells is known to be complex with different isoforms being differentially expressed in various stages of differentiation and in different cell lineages. 11, [44] [45] [46] [47] In BCR-ABL-transformed BaF3 cells, SHIP protein levels were found to be reduced and this effect was regulated by the level of expression of the introduced BCR-ABL. 16 The same group noted that SHIP protein expression was also reduced in several BCR-ABL + human cell lines as well as unseparated preparations of primary CML cells. 16 Here we confirmed the finding of reduced levels of SHIP protein in terminally 
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